BR112012017349A2 - "composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade" - Google Patents

"composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade"

Info

Publication number
BR112012017349A2
BR112012017349A2 BR112012017349A BR112012017349A BR112012017349A2 BR 112012017349 A2 BR112012017349 A2 BR 112012017349A2 BR 112012017349 A BR112012017349 A BR 112012017349A BR 112012017349 A BR112012017349 A BR 112012017349A BR 112012017349 A2 BR112012017349 A2 BR 112012017349A2
Authority
BR
Brazil
Prior art keywords
igf
tonicity agent
pharmaceutical compositions
protein
buffering
Prior art date
Application number
BR112012017349A
Other languages
English (en)
Inventor
Mahler Hanns-Christian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012017349A2 publication Critical patent/BR112012017349A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

patente de invenção: "composições farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade". a presente invenção refere-se a uma composição farmacêutica, compreendendo uma proteína de fator de crescimento de tipo insulina i (igf-i) como ingrediente farmacêutico (api), um agente de tonicidade e um tampão. essa composição pode ser administrada como injeção ou infusão e é especialmente últil para o tratamento, prevenção e/ou atraso de progressão de desordens neurodegenerativas, em particular doença de alzheimer (ad), uma doença de neurônio motor (mnd), em particular esclerose lateral amiotrófica (als) ou atrofia muscualr espinhal (sma) ou uma distrofia muscular (md), em particular distrofia muscular de duchenne (dmd) ou distrofia miotônica (mmd).
BR112012017349A 2009-12-23 2010-12-20 "composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade" BR112012017349A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09180607 2009-12-23
PCT/EP2010/070174 WO2011076702A1 (en) 2009-12-23 2010-12-20 Pharmaceutical compositions comprising igf-1 proteins, a buffering and a tonicity agent

Publications (1)

Publication Number Publication Date
BR112012017349A2 true BR112012017349A2 (pt) 2017-06-13

Family

ID=43598371

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017349A BR112012017349A2 (pt) 2009-12-23 2010-12-20 "composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade"

Country Status (10)

Country Link
US (1) US20110152188A1 (pt)
EP (1) EP2515868A1 (pt)
JP (1) JP2013514340A (pt)
KR (1) KR20120106854A (pt)
CN (1) CN102665682A (pt)
BR (1) BR112012017349A2 (pt)
CA (1) CA2780080A1 (pt)
MX (1) MX2012007102A (pt)
RU (1) RU2012130606A (pt)
WO (1) WO2011076702A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
US20130274235A1 (en) * 2010-10-08 2013-10-17 The General Hospital Corporation Treatment of motor neuron disease
WO2015095650A1 (en) 2013-12-19 2015-06-25 Puretein Bioscience Llc. Methods for treating an animal
TWI820795B (zh) 2015-07-30 2023-11-01 美商拜奧馬林製藥公司 C型利尿鈉肽變異體治療骨骼發育不良之用途
RS63812B1 (sr) * 2018-01-26 2023-01-31 Hoffmann La Roche Il-22 fc kompozicije i postupci primene
WO2023139115A1 (en) * 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486216T2 (de) 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6235488B1 (en) * 1988-09-29 2001-05-22 Agilent Technologies, Inc. Surface preparation for chemical-specific binding
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
WO1993002695A1 (en) * 1991-08-01 1993-02-18 Genentech, Inc. Igf-1 to improve the neural condition
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
CN1246891A (zh) * 1997-02-06 2000-03-08 诺沃挪第克公司 添加和/或除去了连接基团的多肽－聚合物偶联物
US7067485B2 (en) * 1997-11-07 2006-06-27 Chiron Corporation IGF-I composition and its use
AU1384799A (en) * 1997-11-07 1999-05-31 Chiron Corporation Novel igf-i composition and its use
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
AU3764199A (en) * 1998-04-29 1999-11-16 Genentech Inc. Spray dried formulations of igf-i
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DK1141014T3 (da) * 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
AU762047B2 (en) * 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
DK1165119T3 (da) * 1999-04-08 2003-12-15 Genentech Inc Sammensætning baseret på modsat ladede polypeptider
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US20020082215A1 (en) 2000-10-13 2002-06-27 Chiron Corporation Method for treating ischemic events affecting the central nervous system
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
AU2006330858A1 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
ES2388827T3 (es) * 2008-04-03 2012-10-19 F. Hoffmann-La Roche Ag Uso de variantes de IGF-I PEGiladas para el tratamiento de trastornos neuromusculares

Also Published As

Publication number Publication date
EP2515868A1 (en) 2012-10-31
CN102665682A (zh) 2012-09-12
KR20120106854A (ko) 2012-09-26
WO2011076702A1 (en) 2011-06-30
JP2013514340A (ja) 2013-04-25
RU2012130606A (ru) 2014-01-27
US20110152188A1 (en) 2011-06-23
MX2012007102A (es) 2012-07-23
CA2780080A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
BR112012017349A2 (pt) "composição farmacêuticas de proteínas de igf-i, um tamponamento e um agente de tonicidade"
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
PE20091715A1 (es) Variantes de igf-i pegiladas y composiciones que las contienen
BR112014019667A2 (pt) formulação de anticorpo abeta
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
NZ600439A (en) Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
MX2023014354A (es) Compuestos del peptido tirosina tirosina ciclico como moduladores de receptores de neuropeptido y.
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
MX336774B (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida.
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
MX349054B (es) Leptinas altamente solubles.
MX2011005965A (es) Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
MX2012002861A (es) Formulaciones farmaceuticas muy concentradas.
MX338685B (es) Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida.
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
JP2010222367A5 (pt)
BR112012021638A2 (pt) composição livre de conservantes estéril ótica farmacêutica na forma de uma solução aquosa clara.
BR112013033008A2 (pt) "formulação farmacêutica líquida compreendendo nitisinona, seu uso e uso de nitinisona"
WO2013130577A3 (en) Compositions and methods for the treatment of migraine
WO2014085453A3 (en) Small molecule lxr inverse agonists
PE20150345A1 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo
MX2014013091A (es) Composicion farmaceutica.
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]